Navigation Links
VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
Date:8/23/2011

om the company by contacting VIVUS, Inc., Attention: Corporate Secretary, 1172 Castro Street, Mountain View, CA 94040, (650) 934-5200.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy or FORTRESS; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SE
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
2. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
3. VIVUS to Present at Three Upcoming Investor Conferences in March
4. VIVUS Provides Regulatory Update on QNEXA NDA
5. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
6. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
7. VIVUS to Present at Two Upcoming Investor Conferences
8. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Announces Sale of MUSE Assets to Meda
11. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... HIV Vaccine--PHILADELPHIA, May 17 A research team may ... invention of an effective HIV vaccine, by using an ... developers. By using gene transfer technology that produces molecules ... by a virus closely related to HIV -- the ...
... Findings Confirm Glycerin Accelerates the Healing Process , ... Today , a leading expert ... from a study demonstrating that glycerin helps to speed ... resulting in less bruising and skin discoloration.In a double-blinded, ...
Cached Medicine Technology:Novel Vaccine Approach Offers Hope in Fight Against HIV 2Novel Vaccine Approach Offers Hope in Fight Against HIV 3Glycerin Proven to Improve Bruising and Swelling Caused By Trauma to Skin 2
(Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
(Date:7/9/2014)... occurrence of allergic diseases has risen dramatically in Western ... less exposed to microorganisms and have fewer infections than ... , A study by researchers at Sahlgrenska Academy, University ... to examine maturation of the immune system in relation ... rural areas of the Vstra Gtaland Region, half of ...
(Date:7/8/2014)... The UCLA Program in Memory Restoration has been awarded ... Projects Agency (DARPA) for a four -year project aiming ... UCLA team of experts in neurosurgery, engineering, neurobiology, psychology ... test a memory prosthesis in the brain. , Memory ... of the brain encode information, store it and retrieve ...
(Date:7/8/2014)... be three times higher when auditors were visible to ... according to a study in a major Canadian acute ... the Hawthorne effect in hand hygiene compliance monitoring using ... today on-line in the BMJ Quality & Safety ... did the study as part of her Master,s thesis ...
(Date:7/8/2014)... obesity have increased risks of dying at a young ... disease, stroke, diabetes, and kidney and liver diseases, according ... 20 large studies of people from three countries. The ... (NCI), part of the National Institutes of Health, found ... a dramatic reduction in life expectancy compared with people ...
Breaking Medicine News(10 mins):Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:NCI study finds extreme obesity may shorten life expectancy up to 14 years 2
... treating a rare disease does not amount to deficiency ... dismissed the medical negligence claim case to the tune ... whose wife died almost nine years ago here after ... Consumer Disputes Redressal Commission Bench, presided by Justice M ...
... June 1: The apex consumer court in New Delhi on ... that was filed by an Indian born// US scientist Kunal ... he alleged due to the wrongful treatment. ,Making ... the National Consumer Disputes Redressal Commission (NCDRC) was utterly shocking ...
... son of late BJP leader Pramod Mahajan, is 'serious ... hopital here in the wee hours // , while ... ,'Rahul's condition is serious but stable, all his vital ... told PTI. ,Asked about the cause of Mahajan's ...
... United nation today announced that the world would require US ... year 2008.// However, it is not sure from where the ... special session to address the issue of AIDS, UN members ... antiretroviral drugs which has lowered the cost of treatment., ...
... on smoking in public places, which came into effect on ... the ban be suspended for 30 days after tobacco companies ... ,The companies, notably British American Tobacco and Mastermind, ... it came into effect and thus they did not have ...
... 10 million American children get 'spellbound' in local contests every ... Indian American, making it// to the finals of the prestigious ... began Wednesday. ,With the bee's soaring popularity, the ... TV for the first time as 139 boys and 136 ...
Cached Medicine News:Health News:Court Dismisses 143-Crore Claim Against Hospital In Kolkata For Alleged Negligence In Treatment 2Health News:Court Dismisses 143-Crore Claim Against Hospital In Kolkata For Alleged Negligence In Treatment 3Health News:Indian Americans Compete for the Prestigious Spelling Bee Contest 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: